Pancreatic Cancer Research

ResearcherComprehensive Cancer Center ViennaNo recent work listed

Christoph Carl Zielinski

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1440-9013; OpenAlex author ID A5077961608. Sources: OpenAlex.

Their work

Papers
3 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
7
Papers, trials and grants by year

2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 1 paper

Papers 3

  1. SERPINB7 Expression Predicts Poor Pancreatic Cancer Survival Upon Gemcitabine Treatment. Co-author DOI 10.1016/j.tranon.2018.08.019↗
  2. Biochemical and genetic predictors of overall survival in patients with metastatic pancreatic cancer treated with capecitabine and nab-paclitaxel. Co-author DOI 10.1038/s41598-017-04743-0↗
  3. Phase II trial of capecitabine plus nab-paclitaxel in patients with metastatic pancreatic adenocarcinoma. Last author DOI 10.3978/j.issn.2078-6891.2015.107↗

Closest collaborators

The 7 strongest of 7 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Gerald W. Prager · 3 shared papers, 2016–2019 · strength 0.20
  2. Matthias Unseld · 2 shared papers, 2017–2019 · strength 0.15
  3. Markus Kieler · 2 shared papers, 2017–2019 · strength 0.15
  4. Daniela Bianconi · 2 shared papers, 2017–2019 · strength 0.15
  5. Werner Scheithauer · 2 shared papers, 2016–2017 · strength 0.12
  6. Berthold Streubel · 1 shared paper, 2017 · strength 0.06
  7. Martin Schindl · 1 shared paper, 2016 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.